ATE405272T1 - Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin - Google Patents

Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin

Info

Publication number
ATE405272T1
ATE405272T1 AT05756183T AT05756183T ATE405272T1 AT E405272 T1 ATE405272 T1 AT E405272T1 AT 05756183 T AT05756183 T AT 05756183T AT 05756183 T AT05756183 T AT 05756183T AT E405272 T1 ATE405272 T1 AT E405272T1
Authority
AT
Austria
Prior art keywords
cell lymphoma
deazaaminopterin
propargyl
treatment
amount
Prior art date
Application number
AT05756183T
Other languages
English (en)
Inventor
Owen O'connor
Francis Sirotnak
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE405272(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE405272T1 publication Critical patent/ATE405272T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05756183T 2004-05-30 2005-05-31 Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin ATE405272T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52159304P 2004-05-30 2004-05-30

Publications (1)

Publication Number Publication Date
ATE405272T1 true ATE405272T1 (de) 2008-09-15

Family

ID=34971703

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05756183T ATE405272T1 (de) 2004-05-30 2005-05-31 Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin

Country Status (24)

Country Link
US (4) US7622470B2 (de)
EP (1) EP1750716B1 (de)
JP (1) JP5005532B2 (de)
KR (1) KR101189693B1 (de)
CN (2) CN1960734A (de)
AT (1) ATE405272T1 (de)
AU (1) AU2005249516B2 (de)
BR (1) BRPI0510895A (de)
CA (1) CA2565968C (de)
DE (1) DE602005009176D1 (de)
DK (1) DK1750716T3 (de)
ES (1) ES2313365T3 (de)
HK (1) HK1177901A1 (de)
HR (1) HRP20080569T3 (de)
ME (1) ME01087B (de)
MX (1) MXPA06013559A (de)
NO (1) NO337276B1 (de)
NZ (2) NZ551082A (de)
PL (1) PL1750716T3 (de)
PT (1) PT1750716E (de)
RS (1) RS50622B (de)
SI (1) SI1750716T1 (de)
WO (2) WO2005117891A1 (de)
ZA (1) ZA200609266B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8263354B2 (en) 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
BRPI0510895A (pt) 2004-05-30 2007-11-27 Sloan Kettering Inst Cancer formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
US20080188479A1 (en) 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
EP2650379B1 (de) 2007-07-31 2015-09-16 Accera, Inc. Verwendung genomischer und ketogener Verbindungen zur Behandlung von beeinträchtigten kognitiven Funktionen
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US20090048262A1 (en) * 2007-08-17 2009-02-19 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
WO2010003114A1 (en) 2008-07-03 2010-01-07 Neuera Pharmaceuticals, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2010022277A2 (en) * 2008-08-20 2010-02-25 O'connor Owen A Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
ES2596953T3 (es) * 2010-02-02 2017-01-13 Allos Therapeutics, Inc. Diastereómeros de 10-propargil-10-desazaaminopterina para uso en el tratamiento del cáncer de pulmón
JP5897558B2 (ja) * 2010-06-02 2016-03-30 アロス セラピューティクス，インコーポレイテッド １０−プロパルギル−１０−デアザアミノプテリンによりメトトレキサート抵抗性疾患を治療するための方法
RU2013102373A (ru) * 2010-08-10 2014-09-20 Аллос Терапьютикс, Инк. Продления выживаемости без прогрессирования заболевания с применением 10-пропаргил-10-деазааминоптерина
WO2013164856A1 (en) 2012-05-04 2013-11-07 Avra Laboratories Private Limited A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
CN103274943B (zh) * 2013-05-24 2015-01-21 苏州明锐医药科技有限公司 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法
WO2016205203A1 (en) 2015-06-16 2016-12-22 Spectrum Pharmaceuticals, Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393064A (en) 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US4652533A (en) 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
DE69121844T2 (de) 1990-11-20 1997-01-23 Behringwerke Ag Immunotest für Cyclosporin
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
EP2258702A3 (de) * 1996-07-17 2011-11-30 Sloan-Kettering Institute For Cancer Research Gereinigte Zusammensetzungen von 10-Propargyl-10-Deazaaminopterin unde Verfahren zu ihrer Verwendung bei der Behandlung von Tumoren
US6323205B1 (en) 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
BRPI0510895A (pt) * 2004-05-30 2007-11-27 Sloan Kettering Inst Cancer formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t

Also Published As

Publication number Publication date
US8299078B2 (en) 2012-10-30
EP1750716B1 (de) 2008-08-20
US7939530B2 (en) 2011-05-10
KR20110081327A (ko) 2011-07-13
SI1750716T1 (sl) 2009-06-30
ES2313365T3 (es) 2009-03-01
NZ576849A (en) 2011-03-31
RS50622B (sr) 2010-06-30
CN1960734A (zh) 2007-05-09
WO2005117892A1 (en) 2005-12-15
PT1750716E (pt) 2008-11-04
NO20065971L (no) 2006-12-22
JP5005532B2 (ja) 2012-08-22
ZA200609266B (en) 2008-12-31
US20100120777A1 (en) 2010-05-13
PL1750716T3 (pl) 2009-01-30
CN102824346A (zh) 2012-12-19
BRPI0510895A (pt) 2007-11-27
US20130053391A1 (en) 2013-02-28
US20050267117A1 (en) 2005-12-01
EP1750716A1 (de) 2007-02-14
AU2005249516B2 (en) 2010-11-18
NO337276B1 (no) 2016-02-29
KR101189693B1 (ko) 2012-10-10
US20080058280A1 (en) 2008-03-06
HK1177901A1 (en) 2013-08-30
DK1750716T3 (da) 2008-12-08
MXPA06013559A (es) 2007-04-24
ME01087B (me) 2012-12-20
WO2005117891A1 (en) 2005-12-15
CA2565968C (en) 2013-01-08
CA2565968A1 (en) 2005-12-15
NZ551082A (en) 2009-06-26
HRP20080569T3 (en) 2008-12-31
AU2005249516A1 (en) 2005-12-15
CN102824346B (zh) 2015-04-22
JP2008501038A (ja) 2008-01-17
DE602005009176D1 (de) 2008-10-02
US7622470B2 (en) 2009-11-24

Similar Documents

Publication Publication Date Title
ATE405272T1 (de) Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin
ATE302003T1 (de) Zubereitungen enthaltend apomorphin und sildenafil und ihre verwendung zur behandlung von erektiler dysfunktion
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
CY1108217T1 (el) Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης
IS2630B (is) Meðferð á fráhvarfseinkennum
RU2013123646A (ru) Комбинированная композиция
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
RU2009101026A (ru) Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
RU2003113210A (ru) Лечение раковых заболеваний
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
RU2005114664A (ru) Способ лечения хронического панкреатита
DK1697401T3 (da) Tetrapeptid, som regulerer blodglucoseniveauet ved diabetes mellitus
UA3797U (uk) Спосіб лікування тяжких проникаючих поранень ока
RU2001102089A (ru) Способ лечения дисциркуляторной энцефалопатии
RU2002109170A (ru) Способ лечения больных хроническими цереброваскулярными заболеваниями
RU2010143898A (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
RU2007138452A (ru) Способ лечения пушных зверей при отодектозе

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1750716

Country of ref document: EP